Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Urological Cancer Market to 2022 – Strong Growth Driven by Rising Prevalence Increased Uptake of Hormone Therapies and Approval of Novel Biologics

Friday, March 10, 2017 2:36
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Global Urological Cancer Market to 2022 – Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics


  • Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.
  • A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

Get Sample  :

  • Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.


  • Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications?
  • How will the market shares and CAGRs of the top 20 companies compare within this therapy area?
  • What proportion of the key players’ revenues will be attributable to urological cancers?

Enquire About Report :

Reasons to buy

  • This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
  • Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types
  • Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers
  • Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

Also  Request For Discount :

Table Of Contents

  • 1 Table of Contents
  • 1 Table of Contents 4
    • List of Tables 6
    • List of Figures 6
  • Introduction 9
    • Disease Cluster Introduction 9
    • Symptoms 9
    • Etiology and Pathophysiology 10
      • Etiology 10
      • Pathophysiology 11
    • Co-morbidities and Complications 13
    • Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 13
      • Bladder Cancer 14
      • Kidney Cancer 15
      • Prostate Cancer 15
      • Testicular Cancer 16
    • Treatment 17
      • Chemotherapy 17
      • Surgery and Radiation Therapy 19
      • Hormonal Therapies 21
      • Targeted Therapies 22
  • Key Marketed Products 23
    • Overview 23
    • Zytiga (abiraterone acetate) 23
    • Xtandi (enzalutamide) 25
    • Sutent (sunitinib malate) 26
    • Votrient (pazopanib hydrochloride) 27 

Find More Details  : 

About Us

We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities.

Research Beam will always make sure to bring most ethical and high quality reports. We value your relationship with us and look forward for a long term relation.

Contact Us

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.